A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7101-7106

  Fine, Howard A ^a   Kim, Lyndon ^a   Albert, Paul S ^b   Duic, J Paul ^a   Ma, Hilary ^a   Zhang, Wei ^a   Tohnya, Tanyifor ^a   Figg, William D ^a   Royce, Cheryl ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ENZYME INDUCING AGENT; LENALIDOMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE INTERVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HEMANGIOBLASTOMA; HERPES ZOSTER; HUMAN; KERATOCONJUNCTIVITIS; MALE; MAXIMUM TOLERATED DOSE; MENINGIOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOGRAPHY; RECURRENT CANCER; RETINA VEIN OCCLUSION; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE;

EID: 37249075870     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1546     Document Type: Article

References (28)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
2. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growthf actor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
3. Zagzag D, Miller DC, Sato Y, et al. Immunohistochemical localization of basic fibroblast growthf actor in astrocytomas. Cancer Res 1990;50:7393-8.
4. Takahashi JA, Mori H, Fukumoto M, et al. Gene expression of fibroblast growthf actors inhuman gliomas and meningiomas: demonstration of cellular source of basic fibroblast growthf actor mRNA and peptide in tumor tissues. Proc Natl Acad Sci U S A 1990;87:5710-4.
5. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growthi nhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
6. Maxwell M, Naber SP, Wolfe HJ, et al. Expression of angiogenic growthf actor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 1991;51:1345-51.
7. Purow B, Fine HA. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol Oncol Clin North Am 2004;18:1161-81, x.
8. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
9. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15.
10. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
11. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63.
12. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-92.
13. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004;90:955-61.
14. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. JClin Oncol 2006;24:5343-9.
15. Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 2006;107:2609-16.
16. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients withr elapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
17. Tohnya TM, Ng SS, Dahut WL, et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer 2004;2:241-3.
18. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
19. Tohnya TM, Hwang K, Lepper ER, et al. Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;811:135-41.
20. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;21:2299-304.
21. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004;60:353-7.
22. Groves MD, Puduvalli VK, Chang SM, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81:271-7.
23. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-22.
24. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87:1166-72.
25. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-61.
26. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001;7:326-31.
27. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II trials. J Clin Oncol 1999;17:2572-8.
28. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncol 2007;9:29-38.